Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. announced that its subsidiary, Pharmaron Shaoxing, has successfully passed a U.S. FDA on-site inspection, confirming compliance with cGMP pharmaceutical quality standards. This marks a significant milestone as it is the first time the company’s commercial API production facilities in Shaoxing have passed such an inspection for innovative drugs. This achievement aligns Pharmaron’s quality system with international standards, enabling it to supply commercial innovative drug APIs to U.S. and global markets. The successful inspection is expected to positively impact Pharmaron’s growth and expansion within the global CDMO sector, reinforcing its commitment to international quality standards and enhancing its reputation as a reliable partner in the pharmaceutical industry.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$37.50 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, focusing on contract development and manufacturing organization (CDMO) services for innovative pharmaceuticals. The company provides commercial API production solutions across its facilities in China, the U.K., and the U.S., serving global clients with tailored solutions for different markets.
YTD Price Performance: 70.03%
Average Trading Volume: 15,129,363
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.79B
For detailed information about 3759 stock, go to TipRanks’ Stock Analysis page.